News Digest / Ticker: CELC

Ticker: CELC

09:46am, Monday, Aug 19, 2024

Celcuity Inc. Posts Wider Q2 Loss but Gains Momentum with Promising Cancer Drug Trials and Strong Cash Reserves

Celcuity Inc. (NASDAQ: CELC) reported a Q2 2024 net loss of $23.7M, up from $14.6M last year. Despite challenges, the biotech firm is advancing gedatolisib in crucial trials and raised $129M for future initiatives, positioning for potential growth in the cancer treatment market.